company background image
VKTX logo

Viking Therapeutics NasdaqCM:VKTX Stock Report

Last Price

US$65.80

Market Cap

US$7.2b

7D

-0.06%

1Y

556.0%

Updated

18 Oct, 2024

Data

Company Financials +

Viking Therapeutics, Inc.

NasdaqCM:VKTX Stock Report

Market Cap: US$7.2b

Viking Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Viking Therapeutics
Historical stock prices
Current Share PriceUS$65.80
52 Week HighUS$99.41
52 Week LowUS$8.28
Beta1.0
11 Month Change2.09%
3 Month Change29.27%
1 Year Change556.03%
33 Year Change1,042.36%
5 Year Change913.87%
Change since IPO634.38%

Recent News & Updates

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Recent updates

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics: Future Weight Loss Heavyweight?

Apr 02

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13
Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Viking Therapeutics announces senior management appointments

Jan 06

Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Dec 09
Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Viking Therapeutics: Progressing Steadily, But Concerns Remain

Nov 29

Shareholder Returns

VKTXUS BiotechsUS Market
7D-0.06%0.6%0.8%
1Y556.0%27.4%38.3%

Return vs Industry: VKTX exceeded the US Biotechs industry which returned 26.9% over the past year.

Return vs Market: VKTX exceeded the US Market which returned 36% over the past year.

Price Volatility

Is VKTX's price volatile compared to industry and market?
VKTX volatility
VKTX Average Weekly Movement12.7%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: VKTX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VKTX's weekly volatility has decreased from 21% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201229Brian Lianwww.vikingtherapeutics.com

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

Viking Therapeutics, Inc. Fundamentals Summary

How do Viking Therapeutics's earnings and revenue compare to its market cap?
VKTX fundamental statistics
Market capUS$7.16b
Earnings (TTM)-US$96.74m
Revenue (TTM)n/a

0.0x

P/S Ratio

-75.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VKTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$96.75m
Earnings-US$96.74m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Oct 23, 2024

Earnings per share (EPS)-0.87
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did VKTX perform over the long term?

See historical performance and comparison